Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)
No head-to-head trial has compared body composition outcomes between these protocols
Others explore entirely different medications, such as those covered in our phentermine vs tirzepatide comparison
But it has a number of side effects that may make it risky to use for weight loss alone, including constipation
D.DebelouchinaG
Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence